Scarica l'app Stockscreener
85.60
0.81%
-0.70
Dopo l'orario di chiusura:
85.68
0.08
+0.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$86.30
Aprire:
$86.65
Volume 24 ore:
21.13M
Relative Volume:
1.73
Capitalizzazione di mercato:
$149.10B
Reddito:
$45.13B
Utile/perdita netta:
$6.28B
Rapporto P/E:
23.85
EPS:
3.5895
Flusso di cassa netto:
$7.38B
1 W Prestazione:
-2.07%
1M Prestazione:
-6.27%
6M Prestazione:
-33.59%
1 anno Prestazione:
-35.57%
Intervallo 1D:
$85.28
$86.73
Intervallo di 1 settimana:
$84.96
$86.96
Portata 52W:
$81.97
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Abbott Laboratories stock (US0028241000): Insider activity stays in focus - AD HOC NEWS
Is ACS’s Cologuard Endorsement Reshaping the Investment Case for Abbott Laboratories (ABT)? - Yahoo Finance
Trump Clears Way for Companies to Avoid Taxes in Havens Including Malta and Cyprus - The New York Times
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $115 - 富途牛牛
BSX vs. ABT: Which Medical Stock Has More Upside Potential? - TradingView
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
Is Abbott Laboratories Stock Underperforming the Dow? - Barchart
Abbott gets European OK to market world’s first dual glucose-ketone sensor - Crain's Chicago Business
A Look At Abbott Laboratories (ABT) Valuation After New Approvals For Libre Duo And Ultreon 3.0 - simplywall.st
Abbott Laboratories stock (US0028241000): focus on valuation as regulatory AI approvals frame growth - AD HOC NEWS
Abbott Labs Settles Ill. Genetic Privacy Suit - Law360
Abbott Laboratories stock (US0028241000): regulatory clearances for AI cardiology and glucose-ketone - AD HOC NEWS
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views? - Yahoo Finance
Abbott obtains CE mark for duo of glucose-ketone monitors - Yahoo Finance
Abbott Clears AI Cardiology And Dual Sensors As Shares Face Pressure - simplywall.st
Abbott (ABT) Wins FDA and EU Approval for an AI-Powered Tool That Guides Artery Stent Placement - Insider Monkey
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance Singapore
10 Dividend Growth Stocks To Guard Wealth - Sure Dividend
Abbott Labs Settles Illinois Medical History Privacy Lawsuit - Bloomberg Law News
Abbott (ABT) Launches Innovative Dual Glucose-Ketone Monitoring System - GuruFocus
Abbott secures CE mark for dual glucose-ketone sensing technology for diabetes patients - marketscreener.com
Abbott Laboratories stock (US0028241000): investors weigh diagnostics and growth drivers - AD HOC NEWS
Abbott secures CE mark for dual glucose-ketone sensor By Investing.com - Investing.com Canada
Abbott secures CE mark for dual glucose-ketone sensor - Investing.com
Abbott wins CE mark for dual glucose-ketone sensor - Drug Delivery Business
New Abbott sensor tracks glucose and ketones to flag DKA risk - Stock Titan
How Abbott's Diagnostics Unit Is Shaping Up Through the Rest of 2026 - Yahoo Finance
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $113 From $121, Maintains Buy Rating - Moomoo
Abbott (ABT) Sees Cologuard and Cologuard Plus Confirmed in Upda - GuruFocus
ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening - PR Newswire
Abbott Laboratories stock (US0028241000): investors weigh diagnostics strength and medical-device he - AD HOC NEWS
Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026 - PR Newswire
Abbott Laboratories (ABT) Slid on Headwinds in Nutrition Business - Insider Monkey
Why Johnson & Johnson Might Be the Smartest Dividend King to Buy in Today's Market - The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Abbott Laboratories (ABT) Stock Analysis: Tapping Into A 35.73% Potential Upside - DirectorsTalk Interviews
Reassessing Abbott Laboratories (ABT) After A 32% One Year Share Price Decline - Yahoo Finance
Abbott Deepens Digital Health Push With New Cardiovascular Diagnostics And Wearables - simplywall.st
Abbott Laboratories stock is getting decimated, but the smart money senses opportunity - MSN
Abbott Laboratories Stock Is Getting Decimated, But the Smart Money Senses Opportunity - Barchart
Has the Abbott Laboratories Sell-Off Finally Created an Entry Point? - AOL.com
Abbott Laboratories (ABT) Slid Due To Its Nutrition Segment’s Sensitivity to Consumer Spending Momentum - Insider Monkey
Waiting on Integration Result, Market Stays Moderated on Abbott Laboratories (ABT) - Insider Monkey
Three Recession-Resistant Stocks Worth Investors’ Attention - NAI500
Abbott’s Lingo Wearable And Cardio R&D Reframe Long Term Growth Story - Yahoo Finance
Abbott Laboratories, Coca-Cola, and Walmart: Top Recession-Proof Stocks for 2026News and Statistics - IndexBox
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Has the Abbott Laboratories sell-off finally created an entry point? - MSN
Long term debt to total equity ratio of Abbott Laboratories – BVL:ABTUS - TradingView
Abbott Laboratories Balance Sheet – BVL:ABTUS - TradingView
NEC Baby Formula Lawsuit & Settlement | May 2026 Update - Lawsuit Information Center
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.83%
0.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):